ABBV : Analysis & Opinions

  1. Gilead Earnings Preview: What You Should Know

    April 22, 2015
    Perhaps no biotechnology stock has shaped what it means to improve patient quality of care more in recent years than Gilead ...
  2. How Gilead Plans to Keep Competitors in Check

    April 14, 2015
    Gilead Sciences (NASDAQ: GILD) has plenty of experience in outmaneuvering competitors. After all, despite competitors' launching ...
  3. How is a Spinoff Worth $100 Billion? See AbbVie

    April 1, 2015
    An in depth look at Abbott Labs spinoff AbbVie and how it became a nearly $100 billion company.
  4. Read This Before You Sell Gilead Sciences

    March 25, 2015
    Earlier this week, Gilead Sciences (NASDAQ: GILD) reported that nine people who were taking a specific heart disease drug ...
  5. Why These Could Be 2015's 10-Best Pharma Stocks

    March 17, 2015
    The pharmaceutical stocks covered here have significant potential going forward. Here's why.
  6. A Multi-Asset Income ETF For Defensive Investors

    November 14, 2014
    In light of market volatility and worries that stocks are overbought, one product worth noting is the Guggenheim Multi-Asset ...
  7. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  8. Biotechnology Stocks To Keep on the Radar

    April 23, 2014
    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  9. Biotechnology: Some of the Strongest Stocks on Nearly Any Time ...

    September 18, 2013
    Biotechnology is an industry which as has lead the very strong healthcare sector on almost every time frame over the last ...
  10. Pfizer Looking A Little Tired

    July 30, 2013
    Pfizer gets a boost from better margins, but the growth outlook is pretty feeble.
  11. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  12. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  13. Warning: The Rebound May Be Over For Big Pharma

    June 10, 2013
    As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series ...
  14. Strategy for Trading High Flying Healthcare Stocks

    April 17, 2013
    Over the past week, month and three months, the healthcare sector has been the top performer.
  15. Abbott Labs Spins Off AbbVie: Which Is The Better Buy?

    January 4, 2013
    January 2 was the first day of trading for the pharmaceutical spin-off.
Trading Center